Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
T-PHYL vs AMINOPHYLLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
T-PHYL is a theophylline derivative that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors.
Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.
Treatment of asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity
Treatment of acute bronchospasm in asthma and COPD,Treatment of apnea of prematurity,Off-label: adjunctive therapy in COPD exacerbations, status asthmaticus
400 mg orally every 6 hours, or 200 mg orally every 4 hours for sustained-release.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.
7-9 hours in adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, or with CYP1A2 inhibitors
Adults: 7-9 hours (nonsmokers), 4-5 hours (smokers), 10-20 hours (neonates, hepatic impairment, CHF).
Primarily hepatic via cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4; also undergoes N-demethylation and oxidation.
Hepatic metabolism via CYP1A2 and xanthine oxidase; demethylation and oxidation yield active metabolites (caffeine and 3-methylxanthine).
Renal (10% unchanged), hepatic metabolism (90%) with metabolites excreted in urine
Renal: ~10% unchanged; hepatic metabolism (N-demethylation, oxidation) accounts for >80% of elimination; <1% fecal.
40% bound, primarily to albumin
Approximately 40-60% bound to albumin in adults; lower in neonates (20-30%) and patients with hepatic disease.
0.45-0.6 L/kg, approximating total body water; higher in neonates and patients with obesity
0.3-0.7 L/kg (average 0.45 L/kg); increased in neonates, cirrhosis, and CHF.
Oral immediate-release: 96-100%; oral sustained-release: 80-90%
Oral: ~100% (well-absorbed); Rectal: ~80-100% (variable); IM: ~100% (avoid due to pain and unpredictable absorption).
For GFR 10-50 m L/min: administer every 8-12 hours; for GFR <10 m L/min: administer every 12-24 hours.
No specific dose adjustment required based on GFR; monitor theophylline levels closely in renal impairment.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 50-75% or consider alternative.
Starting dose 5 mg/kg/day orally divided every 6 hours; titrate to maximum 10 mg/kg/day.
Oral: 5 mg/kg/dose every 6 hours; IV loading: 5-6 mg/kg; maintenance: 0.5-0.9 mg/kg/hour for ages 6 months-9 years, 0.4-0.5 mg/kg/hour for ages 9-16 years.
Start at lowest effective dose (200 mg every 6 hours) and monitor for toxicity due to reduced clearance.
Reduce initial dose by 50% (e.g., 0.2-0.3 mg/kg/hour IV) due to decreased clearance; monitor serum theophylline levels and titrate slowly.
No FDA black box warning is currently required for T-PHYL.
No FDA boxed warning exists; however, use caution in patients with acute myocardial injury due to potential arrhythmias.
Narrow therapeutic index; monitor serum concentrations. Use with caution in patients with cardiac disorders, hepatic impairment, or peptic ulcer disease. Risk of seizures at high doses. Avoid abrupt discontinuation.
Narrow therapeutic index requiring monitoring of serum theophylline levels; increased seizure risk at high concentrations; arrhythmia risk; caution in heart failure, hepatic impairment, and elderly.
Hypersensitivity to theophylline or any component of the formulation, concomitant use with ephedrine in children.
Hypersensitivity to aminophylline, theophylline, ethylenediamine; uncontrolled arrhythmias; active seizure disorder; peptic ulcer; severe hypertension.
High-protein foods reduce theophylline clearance; high-carbohydrate foods increase clearance. Avoid charcoal-broiled meats and caffeine-containing products (coffee, tea, cola) as they may increase toxicity. Consistency in diet is important to maintain stable serum levels.
Avoid high-fat meals which can decrease absorption and lead to variable serum levels. Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase theophylline toxicity and side effects. Charcoal-broiled foods and a high-protein, low-carbohydrate diet may increase clearance of theophylline. Consistently maintain dietary habits to avoid fluctuations in theophylline levels.
First trimester: Possible increase in congenital malformations (e.g., cardiovascular, neural tube defects) based on animal studies and limited human data. Second/third trimester: Risk of fetal tachycardia, irritability, and neonatal withdrawal with chronic use.
Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the first trimester, limited data do not indicate a significant increase in major malformations, but the drug should be used only if clearly needed. In the second and third trimesters, theophylline may cause fetal tachycardia, jitteriness, and irritability if maternal levels are high. Near term, accumulation of theophylline in the fetus may lead to neonatal withdrawal (irritability, apnea) and transient tachycardia. Risk is dose-dependent and more pronounced at serum levels >15 mcg/m L.
Excreted into breast milk in low amounts (M/P ratio ~0.3-0.5). Use with caution; monitor infant for irritability or poor feeding.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. Infant exposure is estimated to be 1–10% of the maternal weight-adjusted dose. Premature infants or those with impaired clearance are at risk for accumulation and toxicity (irritability, jitteriness, feeding intolerance). Breastfeeding is generally considered acceptable if maternal serum levels are within therapeutic range (5-15 mcg/m L) and the infant is monitored for signs of theophylline toxicity. American Academy of Pediatrics classifies theophylline as compatible with breastfeeding, but caution is advised.
Increased clearance and volume of distribution in pregnancy may require dose increase by 30-50% to maintain therapeutic levels. Monitor serum concentrations closely.
Pregnancy increases the clearance of theophylline by approximately 20-30% due to increased volume of distribution and hepatic metabolism (especially in the second and third trimesters). Doses may need to be increased by 20-30% to maintain therapeutic serum levels. Frequent monitoring of serum theophylline levels (every 1-2 weeks) is recommended to guide dose adjustments. Postpartum, clearance returns to prepregnancy levels within 2-3 months, so doses should be reduced to avoid toxicity.
T-PHYL (theophylline) requires therapeutic drug monitoring to maintain serum concentrations between 5-15 mcg/m L; levels >20 mcg/m L increase toxicity risk. Cigarette smoking induces its metabolism, requiring dose adjustments. Use with caution in patients with CHF, hepatic impairment, or fever, as clearance decreases. Avoid concurrent use of ciprofloxacin, cimetidine, or macrolides which can elevate levels.
1. Aminophylline is a bronchodilator that is a combination of theophylline and ethylenediamine; the ethylenediamine component may cause allergic reactions in sensitive individuals. 2. Monitor serum theophylline levels closely (therapeutic range: 10-20 mcg/m L); toxicity can occur at levels >20 mcg/m L with symptoms including nausea, vomiting, tachycardia, and seizures. 3. Use with caution in patients with severe hypoxemia, and treat with diltiazem or benzodiazepines for seizures if they occur. 4. Aminophylline can cause significant drug interactions, particularly with cimetidine, fluoroquinolones, and macrolide antibiotics which increase theophylline levels. 5. In acute asthma exacerbations, aminophylline is typically reserved for cases not responding to inhaled beta-agonists and corticosteroids due to narrow therapeutic index.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and alcohol; these can alter theophylline levels in your blood.,Report symptoms of toxicity such as nausea, vomiting, insomnia, tremors, or rapid heartbeat.,Do not take over-the-counter medications unless approved by your doctor.,Maintain consistent dietary habits; avoid high-protein or high-carbohydrate diets that affect clearance.
Take this medication exactly as prescribed; do not chew or crush extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects such as nervousness and palpitations.,Notify your doctor immediately if you experience nausea, vomiting, irregular heartbeats, or seizures.,Do not smoke or stop smoking without consulting your doctor, as smoking affects how this medication works.,Keep a record of peak flow readings as directed by your healthcare provider.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about T-PHYL vs AMINOPHYLLINE, answered by our medical review team.
T-PHYL is a Xanthine bronchodilator that works by T-PHYL is a theophylline derivative that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors.. AMINOPHYLLINE is a Xanthine Bronchodilator that works by Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between T-PHYL and AMINOPHYLLINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of T-PHYL is: 400 mg orally every 6 hours, or 200 mg orally every 4 hours for sustained-release.. The standard adult dose of AMINOPHYLLINE is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between T-PHYL and AMINOPHYLLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. T-PHYL is classified as Category C. First trimester: Possible increase in congenital malformations (e.g., cardiovascular, neural tube defects) based on animal studies and limited human data. Second/third trimester: R. AMINOPHYLLINE is classified as Category C. Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.